Efficacy and safety of baricitinib in patients with active rheumatoid arthritis and inadequate response to tumour necrosis factor inhibitors: the 24-week phase 3 RA-BEACON study

O. Zamani; B. Combe; H.-P. Tony; J. S. Burson; H. Tahir; Mikkel Østergaard; B. Augendre-Ferrante; A. Beselin; E. Larsson; M. Casillas; J. Smolen

Efficacy and safety of baricitinib in patients with active rheumatoid arthritis and inadequate response to tumour necrosis factor inhibitors: the 24-week phase 3 RA-BEACON study

O. Zamani
, B. Combe
, H.-P. Tony
, J. S. Burson
, H. Tahir
, Mikkel Østergaard
, B. Augendre-Ferrante
, A. Beselin
, E. Larsson
, M. Casillas
, J. Smolen

Department for Rheumatology and Spine Diseases

Original language	English
Article number	PP21
Journal	Scandinavian Journal of Rheumatology
Volume	45
Issue number	Suppl. 128
Pages (from-to)	21-2
Number of pages	2
ISSN	0300-9742
Publication status	Published - 2016

Cite this

Zamani, O., Combe, B., Tony, H.-P., Burson, J. S., Tahir, H., Østergaard, M., Augendre-Ferrante, B., Beselin, A., Larsson, E., Casillas, M., & Smolen, J. (2016). Efficacy and safety of baricitinib in patients with active rheumatoid arthritis and inadequate response to tumour necrosis factor inhibitors: the 24-week phase 3 RA-BEACON study. Scandinavian Journal of Rheumatology, 45(Suppl. 128), 21-2. Article PP21.

Efficacy and safety of baricitinib in patients with active rheumatoid arthritis and inadequate response to tumour necrosis factor inhibitors: the 24-week phase 3 RA-BEACON study. / Zamani, O.; Combe, B.; Tony, H.-P. et al.
In: Scandinavian Journal of Rheumatology, Vol. 45, No. Suppl. 128, PP21, 2016, p. 21-2.

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

Zamani, O, Combe, B, Tony, H-P, Burson, JS, Tahir, H, Østergaard, M, Augendre-Ferrante, B, Beselin, A, Larsson, E, Casillas, M & Smolen, J 2016, 'Efficacy and safety of baricitinib in patients with active rheumatoid arthritis and inadequate response to tumour necrosis factor inhibitors: the 24-week phase 3 RA-BEACON study', Scandinavian Journal of Rheumatology, vol. 45, no. Suppl. 128, PP21, pp. 21-2.

@article{4029c522811d4df1a465177e5e5ad719,

title = "Efficacy and safety of baricitinib in patients with active rheumatoid arthritis and inadequate response to tumour necrosis factor inhibitors: the 24-week phase 3 RA-BEACON study",

author = "O. Zamani and B. Combe and H.-P. Tony and Burson, \{J. S.\} and H. Tahir and Mikkel {\O}stergaard and B. Augendre-Ferrante and A. Beselin and E. Larsson and M. Casillas and J. Smolen",

year = "2016",

language = "English",

volume = "45",

pages = "21--2",

journal = "Scandinavian Journal of Rheumatology",

issn = "0300-9742",

publisher = "Taylor and Francis Ltd.",

number = "Suppl. 128",

}

TY - ABST

T1 - Efficacy and safety of baricitinib in patients with active rheumatoid arthritis and inadequate response to tumour necrosis factor inhibitors: the 24-week phase 3 RA-BEACON study

AU - Zamani, O.

AU - Combe, B.

AU - Tony, H.-P.

AU - Burson, J. S.

AU - Tahir, H.

AU - Østergaard, Mikkel

AU - Augendre-Ferrante, B.

AU - Beselin, A.

AU - Larsson, E.

AU - Casillas, M.

AU - Smolen, J.

PY - 2016

Y1 - 2016

M3 - Conference abstract in journal

SN - 0300-9742

VL - 45

SP - 21

EP - 22

JO - Scandinavian Journal of Rheumatology

JF - Scandinavian Journal of Rheumatology

IS - Suppl. 128

M1 - PP21

ER -